Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72590
Title:
Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy.
Authors:
Charnley, Natalie; West, Catharine M L; Barnett, C; Brock, Cathryn S; Bydder, Graeme M; Glaser, Mark; Newlands, Edward S; Swindell, Ric; Matthews, Julian C; Price, Patricia M
Abstract:
PURPOSE: To compare the ability of positron emission tomography (PET) to predict response to temozolomide vs. temozolomide plus radiotherapy. METHODS AND MATERIALS: Nineteen patients with high-grade glioma (HGG) were studied. Patients with recurrent glioma received temozolomide 75 mg/m2 daily for 7 weeks (n=8). Newly diagnosed patients received temozolomide 75 mg/m2 daily plus radiotherapy 60 Gy/30 fractions over 6 weeks, followed by six cycles of adjuvant temozolomide 200 mg/m2/day (Days 1-5 q28) starting 1 month after radiotherapy (n=11). [18F]Fluorodeoxyglucose ([18F]FDG) PET scan and magnetic resonance imaging (MRI) were performed at baseline, and 7 and 19 weeks after initiation of temozolomide administration. Changes in glucose metabolic rate (MRGlu) and MRI response were correlated with patient survival. RESULTS: In the temozolomide-alone group, patients who survived>26 vs. <or=26 weeks showed a greater reduction in MRGlu measured at 7 weeks with median changes of -34% and -4%, respectively (p=0.02). PET responders, defined as a reduction in MRGlu>or=25%, survived longer than nonresponders with mean survival times of 75 weeks (95% CI, 34-115 vs. 20 weeks (95% CI, 14-26) (p=0.0067). In the small group of patients studied, there was no relationship between MRI response and survival (p=0.52). For patients receiving temozolomide plus radiotherapy, there was no difference in survival between PET responders and nonresponders (p=0.32). CONCLUSIONS: Early changes in MRGlu predict response to temozolomide, but not temozolomide plus radiotherapy.
Affiliation:
Wolfson Molecular Imaging Centre, Academic Department of Radiation Oncology, The University of Manchester, Christie Hospital NHS Trust, Manchester, United Kingdom. natalie.charnley@mmic.man.ac.uk
Citation:
Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. 2006, 66 (2):331-8 Int. J. Radiat. Oncol. Biol. Phys.
Journal:
International Journal of Radiation Oncology, Biology, Physics
Issue Date:
1-Oct-2006
URI:
http://hdl.handle.net/10541/72590
DOI:
10.1016/j.ijrobp.2006.04.043
PubMed ID:
16839701
Type:
Article
Language:
en
ISSN:
0360-3016
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorCharnley, Natalie-
dc.contributor.authorWest, Catharine M L-
dc.contributor.authorBarnett, C-
dc.contributor.authorBrock, Cathryn S-
dc.contributor.authorBydder, Graeme M-
dc.contributor.authorGlaser, Mark-
dc.contributor.authorNewlands, Edward S-
dc.contributor.authorSwindell, Ric-
dc.contributor.authorMatthews, Julian C-
dc.contributor.authorPrice, Patricia M-
dc.date.accessioned2009-07-06T14:40:42Z-
dc.date.available2009-07-06T14:40:42Z-
dc.date.issued2006-10-01-
dc.identifier.citationEarly change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. 2006, 66 (2):331-8 Int. J. Radiat. Oncol. Biol. Phys.en
dc.identifier.issn0360-3016-
dc.identifier.pmid16839701-
dc.identifier.doi10.1016/j.ijrobp.2006.04.043-
dc.identifier.urihttp://hdl.handle.net/10541/72590-
dc.description.abstractPURPOSE: To compare the ability of positron emission tomography (PET) to predict response to temozolomide vs. temozolomide plus radiotherapy. METHODS AND MATERIALS: Nineteen patients with high-grade glioma (HGG) were studied. Patients with recurrent glioma received temozolomide 75 mg/m2 daily for 7 weeks (n=8). Newly diagnosed patients received temozolomide 75 mg/m2 daily plus radiotherapy 60 Gy/30 fractions over 6 weeks, followed by six cycles of adjuvant temozolomide 200 mg/m2/day (Days 1-5 q28) starting 1 month after radiotherapy (n=11). [18F]Fluorodeoxyglucose ([18F]FDG) PET scan and magnetic resonance imaging (MRI) were performed at baseline, and 7 and 19 weeks after initiation of temozolomide administration. Changes in glucose metabolic rate (MRGlu) and MRI response were correlated with patient survival. RESULTS: In the temozolomide-alone group, patients who survived>26 vs. <or=26 weeks showed a greater reduction in MRGlu measured at 7 weeks with median changes of -34% and -4%, respectively (p=0.02). PET responders, defined as a reduction in MRGlu>or=25%, survived longer than nonresponders with mean survival times of 75 weeks (95% CI, 34-115 vs. 20 weeks (95% CI, 14-26) (p=0.0067). In the small group of patients studied, there was no relationship between MRI response and survival (p=0.52). For patients receiving temozolomide plus radiotherapy, there was no difference in survival between PET responders and nonresponders (p=0.32). CONCLUSIONS: Early changes in MRGlu predict response to temozolomide, but not temozolomide plus radiotherapy.en
dc.language.isoenen
dc.subjectBrain Canceren
dc.subjectCancer Recurrenceen
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntineoplastic Agents, Alkylating-
dc.subject.meshBrain-
dc.subject.meshBrain Neoplasms-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshDacarbazine-
dc.subject.meshDrug Administration Schedule-
dc.subject.meshFemale-
dc.subject.meshFluorodeoxyglucose F18-
dc.subject.meshGlioma-
dc.subject.meshGlucose-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Recurrence, Local-
dc.subject.meshPositron-Emission Tomography-
dc.subject.meshRadiopharmaceuticals-
dc.subject.meshRadiotherapy Dosage-
dc.subject.meshTreatment Outcome-
dc.titleEarly change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy.en
dc.typeArticleen
dc.contributor.departmentWolfson Molecular Imaging Centre, Academic Department of Radiation Oncology, The University of Manchester, Christie Hospital NHS Trust, Manchester, United Kingdom. natalie.charnley@mmic.man.ac.uken
dc.identifier.journalInternational Journal of Radiation Oncology, Biology, Physicsen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.